SINTX TECHNOLOGIES INC (SINT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.62-2.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · SINT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“With the initial commercial sales of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market.
Stated in 2 of 2 supplied quarters. Management reported: “|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and wound-healing properties.” “Sales of industrial parts to aerospace subsidiaries of Fortune 500 companies accounted for the majority of third-quarter revenue.” Revenue was $2.190 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““With the initial commercial sales of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market.”
“The Company remains focused on advancing the commercialization of its silicon nitride-based medical products, expanding its distribution network and developing strategic partnerships designed to supp…”
|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and w…
Stated in 1 of 2 supplied quarters. Management reported: “|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and wound-healing properties.” ““We are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric Olson, Chairman and CEO of SINTX.” Operating income was $-1.635 million in 2026-Q3.
“|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and w…”
|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and w…
Stated in 2 of 2 supplied quarters. Management reported: “|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and wound-healing properties.” “Based on SINTX’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million, Nasdaq determined that the Company complies with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and confirmed that the previously disclosed deficiency matter is now closed.”
“|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and w…”
“Based on SINTX’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million, Nasdaq determined that the Company complies wit…”
|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and w…
Stated in 1 of 2 supplied quarters. Management reported: “|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and wound-healing properties.” “Per the terms of the Warrant, the per share exercise price shall be the closing price of the Company’s Common Stock at the close of the trading day immediately preceding the date of the Call Notice; if fully exercised under the terms of the Warrant, cash proceeds could provide up to $4.0 million in additional capital, while any Warrants or portion of Warrants that the Holders fail to exercise in a timely manner will automatically expire.”
“|| ● | Initiated large-animal in vivo studies evaluating silicon nitride-treated medical textiles, including sutures and wound dressings, to assess their potential antimicrobial, anti-adhesion, and w…”
Exhibit 99.1 SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program SALT LAKE CITY, Utah – July 23, 2026 – SINTX T…
Over the trailing year it converted 1.16x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.